Perry C, Halawani S, Mukherjee S, Ngaba L, Lieu M, Lee W
JCI Insight. 2024; 9(16).
PMID: 39171530
PMC: 11343603.
DOI: 10.1172/jci.insight.177152.
Perlman S
Clin Park Relat Disord. 2024; 10:100255.
PMID: 38798918
PMC: 11126860.
DOI: 10.1016/j.prdoa.2024.100255.
Rodden L, McIntyre K, Keita M, Wells M, Park C, Profeta V
Ann Clin Transl Neurol. 2023; 10(8):1397-1406.
PMID: 37334854
PMC: 10424660.
DOI: 10.1002/acn3.51830.
Vasquez-Trincado C, Dunn J, Han J, Hymms B, Tamaroff J, Patel M
JCI Insight. 2022; 7(9).
PMID: 35531957
PMC: 9090249.
DOI: 10.1172/jci.insight.155201.
Dunn J, Tamaroff J, DeDio A, Nguyen S, Wade K, Cilenti N
Front Neurosci. 2022; 16:818750.
PMID: 35368287
PMC: 8964400.
DOI: 10.3389/fnins.2022.818750.
DNA methylation in Friedreich ataxia silences expression of frataxin isoform E.
Rodden L, Gilliam K, Lam C, Rojsajjakul T, Mesaros C, Dionisi C
Sci Rep. 2022; 12(1):5031.
PMID: 35322126
PMC: 8943190.
DOI: 10.1038/s41598-022-09002-5.
Friedreich's Ataxia related Diabetes: Epidemiology and management practices.
Tamaroff J, DeDio A, Wade K, Wells M, Park C, Leavens K
Diabetes Res Clin Pract. 2022; 186:109828.
PMID: 35301072
PMC: 9075677.
DOI: 10.1016/j.diabres.2022.109828.
Epigenetic Heterogeneity in Friedreich Ataxia Underlies Variable Reactivation.
Rodden L, Gilliam K, Lam C, Lynch D, Bidichandani S
Front Neurosci. 2021; 15:752921.
PMID: 34899161
PMC: 8655727.
DOI: 10.3389/fnins.2021.752921.
Predictors of loss of ambulation in Friedreich's ataxia.
Rummey C, Farmer J, Lynch D
EClinicalMedicine. 2020; 18:100213.
PMID: 31938785
PMC: 6953645.
DOI: 10.1016/j.eclinm.2019.11.006.
Measuring peripheral nerve involvement in Friedreich's ataxia.
Creigh P, Mountain J, Sowden J, Eichinger K, Ravina B, Larkindale J
Ann Clin Transl Neurol. 2019; 6(9):1718-1727.
PMID: 31414727
PMC: 6764626.
DOI: 10.1002/acn3.50865.
Randomized, double-blind, placebo-controlled study of interferon- 1b in Friedreich Ataxia.
Lynch D, Hauser L, McCormick A, Wells M, Dong Y, McCormack S
Ann Clin Transl Neurol. 2019; 6(3):546-553.
PMID: 30911578
PMC: 6414489.
DOI: 10.1002/acn3.731.
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.
Lynch D, Farmer J, Hauser L, Blair I, Wang Q, Mesaros C
Ann Clin Transl Neurol. 2019; 6(1):15-26.
PMID: 30656180
PMC: 6331199.
DOI: 10.1002/acn3.660.
Impact of diabetes in the Friedreich ataxia clinical outcome measures study.
McCormick A, Farmer J, Perlman S, Delatycki M, Wilmot G, Matthews K
Ann Clin Transl Neurol. 2017; 4(9):622-631.
PMID: 28904984
PMC: 5590524.
DOI: 10.1002/acn3.439.
Degenerative Ataxias: challenges in clinical research.
Subramony S
Ann Clin Transl Neurol. 2017; 4(1):53-60.
PMID: 28078315
PMC: 5221462.
DOI: 10.1002/acn3.374.
Mitochondrial iron-sulfur cluster biogenesis from molecular understanding to clinical disease.
Alfadhel M, Nashabat M, Abu Ali Q, Hundallah K
Neurosciences (Riyadh). 2017; 22(1):4-13.
PMID: 28064324
PMC: 5726836.
DOI: 10.17712/nsj.2017.1.20160542.
Progression of Friedreich ataxia: quantitative characterization over 5 years.
Patel M, Isaacs C, Seyer L, Brigatti K, Gelbard S, Strawser C
Ann Clin Transl Neurol. 2016; 3(9):684-94.
PMID: 27648458
PMC: 5018581.
DOI: 10.1002/acn3.332.
Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.
Chutake Y, Lam C, Costello W, Anderson M, Bidichandani S
Nucleic Acids Res. 2016; 44(11):5095-104.
PMID: 26896803
PMC: 4914082.
DOI: 10.1093/nar/gkw107.
Friedreich Ataxia and nephrotic syndrome: a series of two patients.
Shinnick J, Isaacs C, Vivaldi S, Schadt K, Lynch D
BMC Neurol. 2016; 16:3.
PMID: 26755195
PMC: 4709941.
DOI: 10.1186/s12883-016-0526-2.
FXN Promoter Silencing in the Humanized Mouse Model of Friedreich Ataxia.
Chutake Y, Costello W, Lam C, Parikh A, Hughes T, Michalopulos M
PLoS One. 2015; 10(9):e0138437.
PMID: 26393353
PMC: 4579136.
DOI: 10.1371/journal.pone.0138437.
Frataxin levels in peripheral tissue in Friedreich ataxia.
Lazaropoulos M, Dong Y, Clark E, Greeley N, Seyer L, Brigatti K
Ann Clin Transl Neurol. 2015; 2(8):831-42.
PMID: 26339677
PMC: 4554444.
DOI: 10.1002/acn3.225.